Shukra Pharmaceuticals To Invest ₹600 Crore In Robotics Facility

Shukra Pharmaceuticals Ltd. has received a letter of intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for 10 acres of land in the Medical Device Park, Sector 28, Greater Noida, with a planned investment of approximately ₹600 crore. The facility will produce advanced surgical robotics and Boron Neutron Capture Therapy (BNCT) technology, an innovative treatment for complex cancer cases. The project is expected to generate over 900 direct and approximately 2,000 indirect employment opportunities, positioning India at the forefront of health innovation.

Shukra Pharmaceuticals has also today signed a Memorandum of Understanding (MoU) with Borns Medical Robotics Inc. to bring cutting-edge surgical robotics technology to India. The partnership, formalized at an event in New Delhi, will introduce the Veer Surgical Robot; an AI-driven surgical platform designed to enhance precision, safety, and patient outcomes while making advanced healthcare technology accessible to millions of Indians.

Dr. Minakshi Late, CEO and Global Head of Shukra Ltd., emphasized the initiative's national significance: "Our joint venture with Borns is a contribution towards making India Atmanirbhar Bharat, and our efforts will be to make it affordable and accessible to patients who deserve this technology the most. Our efforts will be to make this technology affordable and accessible to patients who deserve it the most, particularly in underserved regions."

Dr. Alexander T. Teichmann, Chief Medical Officer, Borns Medical Robotics Inc., outlined the partnership's broader vision: "This joint venture fuses Borns' cutting-edge AI-driven robotics with Shukra's vision and market reach. Together, we're empowering surgeons, standardizing outcomes, and building scalable healthcare infrastructure across India and Asia: ushering in a new era of affordable, accessible, and high-precision surgery."

"Every Indian deserves access to the best healthcare technology. Our vision is to make world-class technology available in India at affordable prices. Through this partnership with Borns Medical Robotics, we're taking a significant step toward democratizing advanced surgical care and ensuring that cutting-edge robotic surgery is no longer confined to just metro cities or premium healthcare facilities." said Dakshesh Shah, Chairman and Managing Director, Shukra Pharmaceuticals Ltd. 

Dr. Vivek Bindal, Director and Head of Max Institute of Robotic Surgery, Patparganj, who was among the first surgeons to trial the technology, said: "Robotic surgery has revolutionized surgical care, but access has remained limited due to high costs and restricted availability. The introduction of next-generation platforms like Veer marks a transformative shift. With capabilities like single-port surgery, AI-driven safety features, and advanced micro-instruments, we're now witnessing the democratization of this technology. This means high-quality, minimally invasive procedures become more accessible and affordable for a broader patient population across India; empowering surgeons and improving outcomes for those who need it most."

The partnership will establish manufacturing and distribution capabilities in India, creating a robust ecosystem for robotic surgery. The collaboration aims to train surgeons, build infrastructure, and expand access to minimally invasive surgical options across tier-2 and tier-3 cities, where advanced healthcare technology has traditionally been limited.

The first-ever human clinical trial of the Veer Surgical Robot evaluated its safety and efficacy across basic to advanced procedures, with results demonstrating excellent safety, precision, and clinical outcomes, establishing it as a reliable surgical platform. The findings from the trial have been published in leading international journals and reported to the CDSCO. The Veer Surgical Robot is expected to be deployed across leading hospitals beginning in Q2 2026, with plans to scale rapidly across the country.